Close Menu

Diagnostics

News and analysis on diagnostic technologies and applications.

The regulatory submission triggers a milestone payment, and Invitae will issue 5 million shares of its common stock to former ArcherDx securityholders.

Through the partnership, Newsoara will develop and commercialize up to six targeted agents in greater China, while AUM will retain rights to the agents.

The trial is evaluating BP1002 to treat lymphoma and chronic lymphocytic leukemia patients whose tumors overexpress the protein BCL-2.

As adoption of personalized medicines has accelerated over the last four years, so has the number of marketed genetic and exome tests.

The UK-based firm will use the funds to advance its bespoke neoantigen-targeting T-cell therapies for solid cancers including melanoma and NSCLC.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.